Form 4: Palatin Technologies Director Alan Dunton Boosts Stake with Preferred Stock and Warrants Acquisition

Palatin Technologies, Inc. Director Alan W. Dunton has acquired 200 shares of Series D Preferred Stock and 363,636 Series I warrants, signaling increased insider ownership and confidence in the company.

Summary

• Director Alan W. Dunton acquired 200 shares of Series D Preferred Stock on June 13, 2025, for a transaction value of $20,000.
• Each share of Series D Preferred Stock has a stated value of $100 and is convertible into common stock at an initial conversion price of $0.11 per share, equating to 181,818 shares of common stock from this acquisition.
• Mr. Dunton also acquired 363,636 Series I warrants on the same date, with an exercise price of $0.11 per share.
• The Series D Preferred Stock and Series I warrants were sold at a combined offering price of $0.11 per share of common stock obtainable upon conversion of the Series D Convertible Preferred Stock.
• Following these transactions, Mr. Dunton beneficially owns 224,112 shares of Series D Preferred Stock and 420,016 Series I warrants.

Sentiment

Score: 8

Explanation: The acquisition of additional securities by a director is a strong positive signal, indicating confidence in the company's future. While there's potential for dilution, the direct investment by an insider generally outweighs this for overall sentiment.

Positives

• Insider buying by a Director indicates confidence in the company's future prospects.
• Increased beneficial ownership by a key management figure aligns their interests with shareholders.

Negatives

• The acquisition involves convertible preferred stock and warrants, which could lead to future dilution of common stock if converted or exercised.

Risks

• Conversion of Series D Preferred Stock and exercise of Series I warrants are subject to an initial conversion price of $0.11 per share, which could be below market price at the time of conversion/exercise.
• The exercisability of Series I warrants is contingent upon obtaining stockholder approval as required by the NYSE American, introducing a regulatory risk.
• Potential dilution of common stock for existing shareholders upon conversion of preferred stock and exercise of warrants.

Future Outlook

The exercisability of the acquired Series I warrants is contingent upon future stockholder approval as required by NYSE American, and they will expire five years after this approval date.

Industry Context

This insider transaction reflects a director's direct investment in the company, which is generally viewed positively by the market as it signals confidence in the company's strategic direction and future performance within the biotechnology or pharmaceutical industry.

Related Party Transactions

• The transaction itself is a related party transaction, involving the acquisition of securities by a director of the company.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased insider confidence; potential future dilution from conversion/exercise of preferred stock and warrants.
• Company: Receives capital from the sale of preferred stock and warrants.

Next Steps

• Obtain stockholder approval as required by NYSE American for the exercisability of Series I warrants.
• Potential future conversion of Series D Preferred Stock into common stock.
• Potential future exercise of Series I warrants into common stock.

Key Dates

Recommendation

Keywords

Palatin Technologies, PTN, SEC Form 4, Insider Trading, Director Acquisition, Series D Preferred Stock, Series I Warrants, Convertible Securities, Beneficial Ownership, Alan W. Dunton